SEQSTER Selected By MSAA, Owkin Expands Collaboration With Sanofi, Thermo Fisher Scientific Launches New Clinical Registry, More

By Clinical Research Team  

March 27, 2024 | SEQSTER has been selected by the Multiple Sclerosis Association of America (MSAA) for its patient-centricity, 1-Click Records, and cutting-edge longitudinal health record; Owkin adds immunology to Sanofi collaboration; Thermo Fisher Scientific launches a new CorEvitas syndicated clinical registry in generalized pustular psoriasis; and more. 

Owkin has expanded their collaboration with Sanofi to include immunology. In their work with Sanofi on target identification, the team at Owkin used their AI drug target discovery engine to identify the best candidate gene targets with their associated subpopulations of interest. This enables their partners to understand an individual’s unique biology and design tailored treatments. The next phase of the collaboration will be focused on drug positioning within Sanofi’s immunology therapeutic pipeline. Press release

The Multiple Sclerosis Association of America (MSAA) has selected SEQSTER for its patient-centricity, 1-Click Records, and cutting-edge longitudinal health record. MSAA launched the Multiple Sclerosis Implementation Network (MSIN) in collaboration with Novartis Pharmaceuticals Corporation in May 2023. The MSIN is a patient-centric initiative that connects participating healthcare professionals, shares data and experiences, and develops a research-driven data environment. MSIN data infrastructure, powered by SEQSTER's operating system, will connect participating healthcare professionals, spanning from MS comprehensive care centers to community-based neurologists. Press release

Thermo Fisher Scientific has launched a new CorEvitas syndicated clinical registry in generalized pustular psoriasis (GPP). This registry, which is open to enrollment, is CorEvitas’ 10th syndicated disease registry and addresses an unmet need for real-world evidence related to the clinical and patient-reported outcomes of patients with GPP. The new registry will prospectively collect detailed patient-level data enabling assessment of the natural history of the disease and treatment patterns, along with the prevalence and incidence of comorbidities in patients with the disease. Press release

The American College of Cardiology, in collaboration with the Association of Black Cardiologists, has named 50 learners to its 2024-2025 Clinical Trials Research (CTR) program. More than half of the structural heart cardiologists and surgeons will participate in the CTR’s new Project REACH (Research, Equity, and Access for Cardiac Health), an initiative designed to address existing disparities in structural heart clinical trials work. This incoming cohort of learners will participate in a year-long curriculum designed to advance their skills and careers in clinical trials research and ensure that all individuals have the opportunity to contribute as part of the clinical trials research workforce. Press release

Komodo Health unveiled a new self-service solution for rapid patient cohort analysis and insight generation. MapView is the industry’s first and most sophisticated analytics application that allows users without data science expertise to easily extract insights from Komodo’s Healthcare Map. MapView is designed to accelerate decision-making across the Life Sciences enterprise by generating powerful, automated business intelligence for every team and at every stage of the Life Sciences product life cycle, from clinical development and medical strategy to commercialization. Press release

Cure Mito Foundation and Hope for PDCD Foundation, both patient-led foundations focused on advancing research and supporting families affected by Leigh syndrome and Pyruvate Dehydrogenase Complex Deficiency (PDCD), respectively, are excited to announce a launch of a PDCD patient registry. This innovative registry will be led by the Hope for PDCD foundation and hosted on the same registry platform as the well-established Leigh Syndrome patient registry, developed by the Cure Mito Foundation. This strategic move is aimed at enhancing patient convenience and improving data alignment and research effectiveness. Press release

TrialAssure’s flagship product ANONYMIZE 3.0 is now available. ANONYMIZE allows users across the pharmaceutical industry to perform data, document, and image anonymization and redaction using machine learning, natural language processing, and artificial intelligence to share information knowing that patient and company confidential information are protected. The latest version includes features such as: enhanced user experience, with modernized design and intuitive navigation; centralized workbench structure for a comprehensive view of all projects and tasks in one location; and improved risk score visualization to track progress in mitigating re-identification risks. Press release

The Medical University of South Carolina (MUSC) is bringing Flatiron Assist from Flatiron Health to oncology care clinicians at MUSC Hollings Cancer Center. The collaboration between Flatiron Health and MUSC will equip clinicians with advanced cancer care insights from Flatiron Assist, an oncology-specific clinical decision support platform that prioritizes the latest evidence-based medicine, site-preferred pathways, and clinical research at the point of care. Press release

Seattle Children's Research Institute and Genezen have unveiled a strategic manufacturing partnership for Seattle Children's Research Institute's X-linked agammaglobulinemia (XLA) program. This collaborative effort is focused on leveraging Genezen's viral vector process development and cGMP manufacturing expertise to advance Seattle Children's XLA gene therapy program. XLA is a rare primary immunodeficiency condition characterized by abnormally low levels of immunoglobulins, also referred to as antibodies. No cure presently exists for XLA. The primary objective of XLA gene therapy is to genetically modify stem cells from the bone marrow to permit the generation of new B cells and antibody-producing B cells to restore antibody production and bolster the immune system. Press release.  

PatientSight announced a new service that provides a continuous connection between rare disease patients and life science organizations. PatientSight is a subscription-based platform where survey findings are collected, analyzed, and displayed as easily digestible dashboards. The patient journey is organized by disease, treatment, and brand experience. The surveys are recurring throughout the year, enabling life science organizations to examine key insights and trends within a population. PatientSight is also partnered with Rare Patient Voice, a leading recruitment firm connecting patients and family caregivers with opportunities to take part in all types of research studies. Press release

SPT Labtech and RevoluGen announced the successful automation of RevoluGen’s Fire Monkey High Molecular Weight (HMW) DNA extraction chemistry in a bead-based format using SPT Labtech’s firefly automated liquid handling platform. The automated protocol enables the processing of up to 96 samples in parallel to prepare HMW DNA suitable for library preparation for long-read sequencing in under two hours. The results from this collaboration, which was established in 2023, represent a meaningful advance in sample preparation efficiency for long-read DNA sequencing and eliminates the need for highly repetitive, manual pipetting. Press release

Load more comments